MORRIS PLAINS, N.J., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that five posters on its product candidates will be presented at the 55th American Society of Hematology Annual Meeting, scheduled for December 7 – 10, 2013 in New Orleans, LA. Details of the presentations are listed below (all times are in Eastern Time):
Saturday, December 7, 2013
-
Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study (Liebman, et al.)
Poster Session: Disorders of Platelet Number or Function: Poster I
Publication # 1080: 5:30 p.m. – 7:30 p.m.
Ernest N. Morial Convention Center, Hall E
Sunday, December 8, 2013
-
Bispecific Hexavalant Antibodies With Enhanced Trogocytosis For Treatment Of Lupus (Rossi, et al.)
Poster Session: Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: Poster II
Publication # 2282: 6:30 p.m. – 8:30 p.m.
Ernest N. Morial Convention Center, Hall E
-
ImmunoRNase Therapy Of Lymphoma With Novel CD22-Targeting Quadruple Ranpirnase (Liu, et al.)
Poster Session: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster II
Publication # 3075: 6:30 p.m. – 8:30 p.m.
Ernest N. Morial Convention Center, Hall G
-
A New Platform For Trivalent Bispecific Antibodies Used For T-Cell Redirected Killing Of B-Cell Malignancies (Rossi, et al.)
Poster Session: Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Poster II
Publication # 3078: 6:30 p.m. – 8:30 p.m.
Ernest N. Morial Convention Center, Hall G
Monday, December 9, 2013
-
BCR-ABL1 Molecular Remission After 90Y-Epratuzumab Tetraxetan Radioimmunotherapy In CD22+ Ph+ B-ALL: A Potential New Treatment Paradigm (Chevallier, et al.)
Poster Session: Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III
Publication # 3910: 6:00 p.m. – 8:00 p.m.
Ernest N. Morial Convention Center, Hall E
About Immunomedics
Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Our lead product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, we are planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in advanced pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development include 2 antibody-drug conjugates, labetuzumab-SN-38 (IMMU-130) and TROP-2-SN-38 (IMMU-132). We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and multifunctional antibodies. DNL™ is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. We believe that our portfolio of intellectual property, which includes approximately 237 active patents in the United States and more than 400 foreign patents, protects our product candidates and technologies. Our strength in intellectual property has resulted in the top-10 ranking in the 2012 IEEE Spectrum Patent Power Scorecards in the Biotechnology and Pharmaceuticals category. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.
This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with any cash payment that the Company might receive in connection with a sublicense involving a third party and UCB, which is not within the Company's control, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.